A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

An Investigator Initiated Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis

Association of Social Determinants of Health with Brain MRI Outcomes in Individuals with Pediatric Onset Multiple Sclerosis

Disease-modifying Therapy Discontinuation and Outcomes of Older People with Multiple Sclerosis (MS) at a Large Academic MS Center in Toronto, Canada